Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
shire.com

See what CB Insights has to offer

Investments

13

Portfolio Exits

10

Partners & Customers

10

Service Providers

2

About Shire

Shire (NASDAQ: SHPG) is a global biotechnology company that focuses on developing and delivering treatments for patients with rare diseases and other specialty conditions.

Shire Headquarter Location

Block 2 & 3 Miesian Plaza 50-58 Baggot Street Lower

Dublin,

Ireland

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Shire News

PepGen Appoints Noel Donnelly as Chief Financial Officer

Oct 28, 2021

10/28/2021 | 08:05am EDT Message : *Required fields BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc. , a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Noel Donnelly as Chief Financial Officer. Mr. Donnelly is an experienced finance and R&D executive with expertise in financial planning and analysis, strategy, and portfolio management, and has experience in both the pharmaceutical and financial services industries. “Noel brings over 15 years of experience in leadership roles in both the rare disease and neurodegenerative disease space and will be a vital addition to the PepGen team,” said James McArthur, Ph.D., President and Chief Executive Officer of PepGen. “I look forward to leveraging his insights as we progress our corporate and financial goals and work to advance our neuromuscular disease treatments toward the clinic.” Prior to joining PepGen, Mr. Donnelly worked as the CFO at EIP Pharma Inc., a small private biotech in the neurodegenerative disease space. Before joining EIP Pharma, he spent 15 years at Shire PLC in various leadership roles within both research & development (R&D) and finance functions. More recently, Mr. Donnelly was Vice President, R&D Business Operations at Shire, where he established and led key strategic processes and teams including R&D strategy, portfolio prioritization, due diligence and integrations. Mr. Donnelly previously held positions of increasing responsibility within the Shire finance organization, culminating as the Head of R&D Finance. Mr. Donnelly received his MBA with a Concentration in Finance from Babson College and his Bachelor of Science in Nuclear Engineering with a Minor in Economics from the University of Massachusetts-Lowell. “With the completion of a successful Series B financing, PepGen is well-capitalized to execute on its current development plans,” Donnelly said. “It’s an honor to join the team as CFO and I look forward to continuing the forward momentum needed to make a lasting impact on people living with neuromuscular diseases and their families.” About PepGen  PepGen, Inc. is a biotechnology company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases. PepGen’s proprietary Enhanced Delivery Oligonucleotides (EDOs) are designed to target the underlying causes of rare genetic diseases safely and effectively such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). In preclinical studies, PepGen’s enhanced delivery peptides demonstrated success in cell penetration and delivery of therapeutic candidates to multiple tissue types, including cardiac tissue. PepGen was founded by leading neurology researchers in Oxford, UK and is backed by a strong syndicate of investors including RA Capital Management, Oxford Science Enterprises, and others. The company is headquartered in Boston, Mass. For more information, visit  www.pepgen.com  or follow PepGen on  Twitter  and  LinkedIn . Media Contact

Shire Investments

13 Investments

Shire has made 13 investments. Their latest investment was in Rani Therapeutics as part of their Series D - II on February 2, 2018.

CBI Logo

Shire Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/8/2018

Series D - II

Rani Therapeutics

$53M

Yes

8

1/5/2017

Series C

Translate Bio

$51M

Yes

3

9/7/2016

Series E

Proclara Biosciences

$47M

No

12

1/14/2015

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

3/25/2014

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/8/2018

1/5/2017

9/7/2016

1/14/2015

3/25/2014

Round

Series D - II

Series C

Series E

Series D - II

Series D

Company

Rani Therapeutics

Translate Bio

Proclara Biosciences

Subscribe to see more

Subscribe to see more

Amount

$53M

$51M

$47M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

3

12

10

10

Shire Portfolio Exits

10 Portfolio Exits

Shire has 10 portfolio exits. Their latest portfolio exit was Rani Therapeutics on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$99M

4

7/18/2019

IPO

$99M

2

6/28/2018

IPO

$99M

5

4/16/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

1/4/2017

Divestiture

Subscribe to see more

Subscribe to see more

10

Date

7/30/2021

7/18/2019

6/28/2018

4/16/2018

1/4/2017

Exit

IPO

IPO

IPO

Divestiture

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

2

5

10

10

Shire Acquisitions

21 Acquisitions

Shire acquired 21 companies. Their latest acquisition was sanaplasma on September 07, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/7/2018

$99M

Acquired

1

1/22/2016

Other Venture Capital

$99M

$48.8M

Acq - P2P

1

1/11/2016

$99M

Acq - P2P

2

8/3/2015

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

2/24/2015

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/7/2018

1/22/2016

1/11/2016

8/3/2015

2/24/2015

Investment Stage

Other Venture Capital

Other

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$48.8M

$99M

$99M

Note

Acquired

Acq - P2P

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Shire Partners & Customers

10 Partners and customers

Shire has 10 strategic partners and customers. Shire recently partnered with SeriousFun Children's Network on December 12, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

12/19/2018

Partner

SeriousFun Children's Network

United States

Shire’s Partnership with SeriousFun Children’s Network Enabled Nearly 1,000 Children with Serious Illnesses to Attend Life-Changing Camps

`` Our partnership with SeriousFun has been a high-impact investment in the lives of children with rare diseases and other serious conditions and their families , '' said Linn Parrish , Shire 's Head of Corporate Responsibility .

1

12/17/2018

Vendor

Rentschler Biopharma

Germany

News - Press Releases and Announcements - Detail - Rentschler Biopharma Rentschler Biopharma SE to Purchase U.S. Manufacturing Site from Shire plc.

Laupheim , Germany and Milford , MA , USA , December 17 , 2018 -- Rentschler Biopharma , a leading contract development and manufacturing organization for biopharmaceuticals , announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston , MA , USA .

1

11/8/2018

Licensee

Mirum Pharmaceuticals

United States

Shire agrees to license rare liver disease candidates to Mirum

The financing round was led by New Enterprise Associates and the participants include Deerfield Management , Frazier Healthcare Partners , Novo Holdings , Pappas Capital , RiverVest Venture Partners and Rock Springs Capital .

4

11/5/2018

Licensee

Soleo Health

United States

Subscribe to see more

Subscribe to see more

10

3/26/2018

Partner

NIBRT

Ireland

Subscribe to see more

Subscribe to see more

10

Date

12/19/2018

12/17/2018

11/8/2018

11/5/2018

3/26/2018

Type

Partner

Vendor

Licensee

Licensee

Partner

Business Partner

SeriousFun Children's Network

Rentschler Biopharma

Mirum Pharmaceuticals

Soleo Health

NIBRT

Country

United States

Germany

United States

United States

Ireland

News Snippet

Shire’s Partnership with SeriousFun Children’s Network Enabled Nearly 1,000 Children with Serious Illnesses to Attend Life-Changing Camps

`` Our partnership with SeriousFun has been a high-impact investment in the lives of children with rare diseases and other serious conditions and their families , '' said Linn Parrish , Shire 's Head of Corporate Responsibility .

News - Press Releases and Announcements - Detail - Rentschler Biopharma Rentschler Biopharma SE to Purchase U.S. Manufacturing Site from Shire plc.

Laupheim , Germany and Milford , MA , USA , December 17 , 2018 -- Rentschler Biopharma , a leading contract development and manufacturing organization for biopharmaceuticals , announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston , MA , USA .

Shire agrees to license rare liver disease candidates to Mirum

The financing round was led by New Enterprise Associates and the participants include Deerfield Management , Frazier Healthcare Partners , Novo Holdings , Pappas Capital , RiverVest Venture Partners and Rock Springs Capital .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

4

10

10

Shire Service Providers

2 Service Providers

Shire has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Shire Team

14 Team Members

Shire has 14 team members, including former President, Paul Firuta.

Name

Work History

Title

Status

Paul Firuta

President

Former

Felipe Florez-Arango

Chief Financial Officer

Former

Jeff Poulton

Indigo Diabetes, Indigo Ag, Cinergy, PPG Industries, and U.S. Navy

Chief Financial Officer, Senior Vice President

Former

Joanne Tzouvalopoulos Beck

Senior Vice President

Former

Randy Brenner

Senior Vice President

Former

Name

Paul Firuta

Felipe Florez-Arango

Jeff Poulton

Joanne Tzouvalopoulos Beck

Randy Brenner

Work History

Indigo Diabetes, Indigo Ag, Cinergy, PPG Industries, and U.S. Navy

Title

President

Chief Financial Officer

Chief Financial Officer, Senior Vice President

Senior Vice President

Senior Vice President

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.